Bionyra Pharma
Develops biologic therapies for inflammatory diseases, backed by a large Series A launch financing to advance its pipeline.
Overview
Bionyra Pharma is a France-based biotechnology company launched to develop biologic therapies for inflammatory diseases. Its work targets the pharmaceutical and healthcare markets focused on treating immune-mediated and inflammatory conditions. The company’s main disclosed differentiator is its launch with substantial Series A capital, giving it resources to advance its biologics pipeline from inception. Bionyra raised €143 million, reported as $165 million, in a June 2026 Series A round.
Funding History
France’s Bionyra Pharma launches with €143 million Series A to advance inflammatory disease biologics
Frequently Asked Questions
- How much has Bionyra Pharma raised in total?
- Bionyra Pharma has raised a total of $165M across 1 funding round.
- Who are Bionyra Pharma's investors?
- Bionyra Pharma's investors include VIVES Partners, Jeito Capital, Sofinnova Partners, Arkin Bio, Sanofi Ventures, and 2 others.
- What does Bionyra Pharma do?
- Bionyra Pharma is a France-based biotechnology company launched to develop biologic therapies for inflammatory diseases. Its work targets the pharmaceutical and healthcare markets focused on treating immune-mediated and inflammatory conditions. The company’s main disclosed differentiator is its launch with substantial Series A capital, giving it resources to advance its biologics pipeline from inception. Bionyra raised €143 million, reported as $165 million, in a June 2026 Series A round.
- Where is Bionyra Pharma headquartered?
- Bionyra Pharma is headquartered in San Francisco, CA.
Investors
Related Insights
A comprehensive analysis of Isembard's funding history, investors, competitive position, and growth trajectory in the Deep Tech space.
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
395 AI funding deals worth $337B tracked in 2026. Complete guide to raising pre-seed, seed, Series A/B/C+ for AI startups. Valuations, metrics VCs demand, top investors (Sequoia, a16z, Lightspeed), and how AI funding differs from traditional tech. Includes real deal sizes, timelines, and founder strategies.